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OR
w
D
K
T
Y
M
a
U
b
c
d
e
f
g
h
i
j
a
A
R
R
A
A
K
H

D
L
I
t
a
M
3
0
hJournal of Cardiology 63 (2014) 424–431
Contents lists available at ScienceDirect
Journal  of  Cardiology
jo u r nal homep age: www.elsev ier .com/ locate / j j cc
riginal  article
elation  of  risk  factors  with  response  to  carvedilol  in  heart  failure
ith  preserved  ejection  fraction  –  A  report  from  the  Japanese
iastolic  Heart  Failure  Study  (J-DHF)
azuhiro  Yamamoto  (MD,  FJCC)a,∗,  Hideki  Origasa  (PhD)b, Yasushi  Suzuki  (MD)c,
oshiaki  Takahashi  (MD)d, Tsuyoshi  Shinozaki  (MD,  FJCC)e,  Tomoyuki  Watanabe  (MD)f,
asushi  Sakata  (MD)g,  Chisato  Izumi  (MD,  FJCC)h,  Kayano  Taira  (MD) i,
asatsugu  Hori  (MD,  FJCC) j,  on  behalf  of  the  J-DHF  Investigators1
Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori
niversity, Yonago, Japan
Division of Biostatistics and Clinical Epidemiology, University of Toyama Graduate School of Medicine, Toyama, Japan
Department of Cardiology, Honjo Daiichi Hospital, Yurihonjyo, Japan
Department of Cardiology, Hiraka General Hospital, Yokote, Japan
Department of Cardiovascular Medicine, Sendai Medical Center, Sendai, Japan
Division of Cardiology and Internal Medicine, Health Co-op. Watari Hospital, Fukushima, Japan
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan
Department of Cardiology, Tenri Hospital, Tenri, Japan
Department of Cardiovascular Medicine, Yonezawa City Hospital, Yonezawa, Japan
Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 11 September 2013
eceived in revised form 10 October 2013
ccepted 25 October 2013
vailable online 25 November 2013
eywords:
eart failure
-Blocker
iastole
eft atrium
a  b  s  t  r  a  c  t
Background:  The  Japanese  Diastolic  Heart  Failure  Study  (J-DHF)  has  suggested  beneﬁcial  effects  of the
standard-dose  prescription  of  carvedilol  in  heart  failure  with  preserved  ejection  fraction  (HFPEF).  How-
ever, it is  unclear  whether  any  risk  factors  modulate  the  effects  of  the  standard-dose  carvedilol.
Methods  and  results:  Data  from  245  patients  with  HFPEF  in J-DHF  were evaluated.  Decreased  body  mass
index,  diabetes  mellitus,  and  left  atrial  (LA)  dilatation  were  independent  risk factors  for  both  of  the
primary  outcomes  (cardiovascular  death and  unplanned  hospitalization  for  heart  failure)  and  another
major  composite  outcome  (cardiovascular  death  and unplanned  hospitalization  for any  cardiovascular
causes)  in multivariable  analysis.  In  patients  with  LA diameter  ≥  the  median  value  (43.2 mm),  standard-
dose  carvedilol  was  associated  with  unadjusted  hazard  ratio (HR)  0.263  [95%  conﬁdence  interval  (CI):
0.080–0.859]  and  covariate  adjusted  0.264  (0.080–0.876)  for the  primary  outcome.  In those  with  LA
diameter  < 43.2  mm,  unadjusted  and  adjusted  HRs  were  1.123  (0.501–2.514)  and  1.067  (0.472–2.412).
A  p-value  for  interaction  was  0.046  (unadjusted)  and 0.058  (adjusted).  The  similar  effects  of  LA diame-
ter  were observed  regarding  another  major  composite  outcome.  The  other  risk  factors  in univariate  or
multivariable  analyses  did  not  inﬂuence  the  response  to the  standard-dose  carvedilol.
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ntroductionHeart failure with preserved left ventricular (LV) ejection frac-
ion (EF) (HFPEF) consists of about half of heart failure in clinical
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ttp://dx.doi.org/10.1016/j.jjcc.2013.10.014e  carvedilol  may  exert  greater  reduction  of the  incidence  of clinical  out-
PEF  and  advanced  rather  than  mild  diastolic  dysfunction.
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practice, and its prognosis is as poor as that of heart failure with
reduced EF (HFREF) [1,2]. Despite a big burden of HFPEF, risk
factors of its clinical outcomes remain to be fully explored. In addi-
tion, there is currently no established pharmacological therapy for
HFPEF. Recently, the Japanese Diastolic Heart Failure Study (J-DHF)
has suggested beneﬁcial effects of the standard-dose, not low-dose,
prescription of -blocker carvedilol in patients with HFPEF [3].
However, it is unclear whether any factors modulate the effects
of the standard-dose carvedilol in HFPEF.
We  analyzed the data from J-DHF to determine the risk fac-
tors for clinical outcomes in patients with HFPEF, and to assess the
vier Ltd. All rights reserved.
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Table 1 shows the baseline characteristics of the control and
standard-dose groups. There was  no signiﬁcant difference in any
factors.
Table 1
Patient characteristics of both groups.
Control Standard-dose p-Value
n 187 58
Age (years) 72±11 72±10 0.95
Female (% of patients) 81 (43.3%) 22 (37.9%) 0.47
NYHA I 34 11 0.72
II  135 42
III  14 5
IV  4 0
SAS score (METs) 5.1 ± 1.8 5.2 ± 1.7 0.71
Heart rate (bpm) 73 ± 12 73 ± 13 0.95
Atrial ﬁbrillation 66 (36.3%) 17 (29.3%) 0.33
Systolic blood pressure (mmHg) 133 ± 21 136 ± 22 0.45
Diastolic blood pressure (mmHg) 74 ± 13 77 ± 14 0.11
Body mass index (kg/m2) 23.9 ± 4.2 24.8 ± 4.2 0.20
Etiology of heart failure 0.52
Non-ischemic 158 (84.5%) 51 (87.9%)
Morbidity
Hypertension 150 (80.2%) 47 (81.0%) 0.89
Ischemic heart disease 53 (28.3%) 11 (19.0%) 0.16
Atrial ﬁbrillation 86 (46.0%) 32 (55.2%) 0.22
Diabetes mellitus 63 (33.7%) 12 (20.7%) 0.06
Dyslipidemia 76 (40.6%) 24 (41.4%) 0.92
Cerebrovascular disease 25 (13.4%) 5 (8.6%) 0.34
History of hospitalization for heart
failure
115 (61.5%) 32 (55.2%) 0.39
Medications
ACEI 43 (23.0%) 14 (24.1%) 0.86
ARB  99 (52.9%) 32 (55.2%) 0.77
ACEI or ARB 130 (69.5%) 43 (74.1%) 0.50
Diuretics 109 (58.3%) 38 (65.5%) 0.33
Mineralocorticoid receptor
blockers
45 (24.1%) 12 (20.7%) 0.60
Digoxin 35 (18.7%) 15 (25.9%) 0.24
Calcium channel blockers 89 (47.6%) 29 (50.0%) 0.75
Hemoglobin (g/dl) 12.6 ± 2.0 13.1 ± 1.7 0.06
Serum creatinine level (mg/dl) 1.01 ± 0.43 0.97 ± 0.36 0.51
Estimated glomerular ﬁltration rate
(ml/min/1.73 m2)
57.6 ± 20.4 59.8 ± 20.3 0.48
B-type natriuretic peptide (pg/ml) 217.7 ± 253.6 256.8 ± 376.3 0.37
Norepinephrine (pg/ml) 659.3 ± 425.9 687.9 ± 561.6 0.68
Left  ventricular end-diastolic
dimension (mm)
50 ± 8 50 ± 7 0.96
Left  ventricular ejection fraction (%) 62 ± 10 62 ± 11 0.93
Left  ventricular mass index (g/m2.7) 64 ± 26 61 ± 21 0.38
Relative wall thickness 0.42 ± 0.12 0.41 ± 0.09 0.48K. Yamamoto et al. / Journal
nteraction between the risk factors and the effects of standard-
ose carvedilol.
ethods
The J-DHF design and results have been described and reported
reviously [3,4]. In brief, J-DHF was a multicenter, prospective, ran-
omized, open, blinded endpoint (PROBE) trial to assess the effects
f carvedilol in HFPEF patients in Japan, and enrolled 245 patients
ged ≥20 years with clinical diagnosis of heart failure according to
odiﬁed Framingham criteria within 12 months and LVEF of >40%.
n no patient were there changes in baseline therapy and symptoms
f heart failure within a month before the entry. Main exclusion
riteria were arrhythmogenic right ventricular cardiomyopathy;
recapillary pulmonary artery hypertension; acute myocardial
nfarction within 3 months; or on the waiting list for percutaneous
oronary intervention or open heart surgery. Other criteria have
een previously described in detail [4]. The primary outcome was a
omposite of cardiovascular death and unplanned hospitalization
or heart failure, and another major composite outcome consisted
f cardiovascular death and unplanned hospitalization for any car-
iovascular causes. Deaths and hospitalizations were adjudicated
y a blinded independent Endpoint Committee, using prespeciﬁed
riteria. Association of each baseline variable to the outcomes was
etermined using the data of all 245 subjects.
roups
In the protocol of J-DHF, the enrolled 245 patients were ran-
omly assigned into those treated with (n = 120) and without
arvedilol (n = 125). The planned target dose of carvedilol was
0 mg/day [4], but the results showed that median prescribed
ose was 7.5 mg/day [3]. We  found that the hazard ratio (HR)
f the patients treated with carvedilol > 7.5 mg/day for the pri-
ary outcome and another major composite outcome was  0.649
95% conﬁdence interval (CI) 0.332 to 1.269; p = 0.2062] and 0.539
95% CI 0.303 to 0.959, p = 0.0356) as compared to the patients
ithout carvedilol, respectively. However, HR of the patients
reated with carvedilol ≤ 7.5 mg/day for the outcomes was  1.235
95% CI 0.683 to 2.236; p = 0.4850) and 1.070 (95% CI 0.650 to
.763; p = 0.7893) compared to the patients without carvedilol,
espectively, although the severity of heart failure was compara-
le between the patients treated with carvedilol > 7.5 mg/day and
7.5 mg/day [3]. Therefore, treatment with carvedilol ≤ 7.5 mg/day
ould be regarded as similar to the treatment without carvedilol.
o assess the interaction between the risk factors and the beneﬁ-
ial effects of standard-dose carvedilol in this study, the enrolled
atients were collapsed above and below the median of the
rescribed dose of carvedilol; patients treated with carvedilol
f >7.5 mg/day (standard-dose, n = 58) and those treated with
arvedilol of ≤7.5 mg/day or no prescription of carvedilol (control,
 = 187).
tatistical analysis
All analyses were conducted in accordance with the intention-
o-treat principle. Values are expressed as mean ± standard
eviation (SD). Differences between groups were assessed with
he 2 test for categorical data and Student’s t-tests or Wilcoxon
ank-sum test for continuous data. Cumulative event-free curves
ere constructed by means of Kaplan–Meier methods, and differ-
nces between the groups were evaluated with the use of log-rank
ests. Univariate and multivariable Cox proportional hazards anal-
ses were conducted to explore for the risk factors for clinical
utcomes in HFPEF. In addition to prescription of standard-dose
arvedilol, eight selected variables [age, body mass index (BMI),diology 63 (2014) 424–431 425
history of diabetes mellitus, hemoglobin, estimated glomerular
ﬁltration rate (eGFR), B-type natriuretic peptide (BNP), LV mass
indexed for height2.7 (LV mass index), and left atrial (LA) dimen-
sion] were included in the multivariate model since they were
clinically important and determined to be signiﬁcantly related to
both clinical outcomes from the univariate analysis. To examine
the predictive factors of the effects of standard-dose carvedilol as
compared to either low-dose carvedilol or none for clinical out-
comes, the Cox proportional hazards model was applied with use
of the interactive term between risk factor and treatment group as
well as the main effects in the presence of prespeciﬁed covariates
(age, sex, etiology, and LVEF). Statistical signiﬁcance was  deﬁned by
two-sided 5% and the analyses were performed by SAS statistical
software version 9.1 (Cary, NC, USA).
ResultsLeft  atrial dimension (mm) 45 ± 9 43 ± 7 0.24
Data are shown as mean ± SD. ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; NYHA, New York Heart Association; SAS, speciﬁc
activity scale.
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Table 2
Results of univariate Cox proportional hazards models for the clinical outcomes.
HR (95% CI) p-Value
Primary endpoint
Age 1.031 (1.004–1.059) 0.027
Female 1.056 (0.638–1.750) 0.83
NYHA 1.212 (0.759–1.934) 0.42
SAS  score 0.912 (0.788–1.055) 0.21
Heart rate 1.007 (0.987–1.026) 0.51
Changes in heart rate a year
after the enrollment
1.009 (0.991–1.029) 0.32
Systolic blood pressure 0.998 (0.986–1.010) 0.73
Changes in systolic blood
pressure a year after the
enrollment
1.005 (0.993–1.018) 0.43
Diastolic blood pressure 0.984 (0.964–1.005) 0.13
Body mass index 0.928 (0.878–0.982) 0.0090
Etiology of heart failure
Ischemic 1.361 (0.724–2.556) 0.34
Morbidity
Hypertension 0.695 (0.389–1.244) 0.22
Ischemic heart disease 1.164 (0.672–2.015) 0.59
Atrial ﬁbrillation 1.378 (0.836–2.274) 0.21
Diabetes mellitus 2.262 (1.377–3.716) 0.0013
Dyslipidemia 0.937 (0.567–1.549) 0.80
Cerebrovascular disease 2.050 (1.090–3.855) 0.026
History of hospitalization for 1.683 (0.981–2.887) 0.05926 K. Yamamoto et al. / Journal
The primary outcome occurred in 51 patients (27.3%) of the con-
rol group and 12 patients (20.7%) of the standard-dose group. HR
or the primary outcome in the standard-dose group was  0.610 (95%
I 0.320–1.160; log-rank test p = 0.13) (Fig. 1A). Another composite
ajor outcome occurred in 75 patients (40.1%) of the control group
nd 15 patients (25.9%) of the standard-dose group. HR for this com-
osite major outcome in the standard-dose group was  0.529 (95%
I 0.303–0.924; log-rank test p = 0.018) (Fig. 1B).
ssociation between baseline characteristics and clinical outcomes
Table 2 shows HR of each clinical factor for the primary outcome
nd another major composite outcome in a univariate analysis.
ging, diabetes mellitus, increases in creatinine, BNP, LV mass
ndex, and LA dimension, and decreases in BMI, hemoglobin, and
GFR were risk factors for both clinical outcomes. In addition, cere-
rovascular disease and an increase in LV end-diastolic dimension
ere associated with the primary outcome, and a decrease in EF
as associated with another major composite outcome.
In a multivariable analysis (Table 3), BMI, diabetes mellitus,
nd LA dimension were independently associated with both clin-
cal outcomes. In addition, LV mass index was an independent
isk factor for the primary endpoint, and BNP and prescription of
tandard-dose carvedilol were for another major composite out-
ome.
ig. 1. Kaplan–Meier curves of the primary outcome (a composite of cardiovascular
eath and unplanned hospitalization for heart failure) (A) and another major com-
osite outcome (a composite of cardiovascular death and unplanned hospitalization
or  any cardiovascular causes) (B). The curves of standard-dose group in both ﬁgures
ere reproduced from Yamamoto et al. [3].
heart failure
Medications
Standard-dose carvedilol 0.615 (0.326–1.161) 0.13
ACEI 0.863 (0.468–1.592) 0.64
ARB 1.018 (0.616–1.681) 0.95
ACEI or ARB 1.010 (0.587–1.739) 0.97
Diuretics 1.325 (0.783–2.243) 0.29
Mineralocorticoid receptor
blockers
1.341 (0.776–2.317) 0.29
Digoxin 0.825 (0.439–1.549) 0.55
Ca  channel blocker 1.271 (0.774–2.088) 0.34
Hemoglobin 0.759 (0.663–0.868) <0.0001
Serum creatinine level 3.161 (2.011–4.968) <0.0001
Estimated glomerular ﬁltration
rate
0.976 (0.962–0.989) 0.0004
B-type natriuretic peptide 1.001 (1.001–1.002) <0.0001
Norepinephrine 1.000 (1.000–1.001) 0.098
Left ventricular end-diastolic
dimension
1.040 (1.007–1.074) 0.017
Left ventricular ejection
fraction
0.981 (0.958–1.005) 0.12
Left ventricular mass index 1.014 (1.006–1.022) 0.0007
Relative wall thickness 2.327 (0.247–21.903) 0.46
Left atrial dimension 1.048 (1.019–1.077) 0.0009
Composite of cardiovascular death and unplanned hospitalization for
any  cardiovascular causes
Age 1.023 (1.002–1.045) 0.035
Female 1.020 (0.671–1.549) 0.93
NYHA 1.192 (0.807–1.760) 0.38
SAS  score 0.949 (0.844–1.067) 0.38
Heart rate 1.004 (0.987–1.020) 0.66
Changes in heart rate a year
after the enrollment
1.014 (0.999–1.030) 0.072
Systolic blood pressure 1.005 (0.994–1.015) 0.38
Changes in systolic blood
pressure a year after the
enrollment
1.006 (0.996–1.017) 0.23
Diastolic blood pressure 1.001 (0.984–1.017) 0.93
Body mass index 0.952 (0.909–0.998) 0.040
Etiology of heart failure
Ischemic 1.306 (0.770–2.215) 0.32
Morbidity
Hypertension 0.785 (0.478–1.291) 0.34
Ischemic heart disease 1.287 (0.823–2.012) 0.27
Atrial ﬁbrillation 1.292 (0.854–1.954) 0.22
Diabetes mellitus 1.919 (1.260–2.923) 0.0024
Dyslipidemia 1.422 (0.940–2.150) 0.096
Cerebrovascular disease 1.721 (0.987–2.999) 0.056
History of hospitalization for
heart failure
1.276 (0.829–1.966) 0.27
K. Yamamoto et al. / Journal of Car
Table  2 (Continued)
HR (95% CI) p-Value
Medications
Standard-dose carvedilol 0.518 (0.297–0.903) 0.021
ACEI 0.980 (0.601–1.597) 0.93
ARB 1.107 (0.729–1.679) 0.63
ACEI or ARB 1.215 (0.764–1.931) 0.41
Diuretics 0.972 (0.637–1.482) 0.89
Mineralocorticoid receptor
blockers
0.975 (0.598–1.591) 0.92
Digoxin 0.973 (0.586–1.615) 0.92
Ca  channel blocker 1.043 (0.690–1.577) 0.84
Hemoglobin 0.853 (0.764–0.952) 0.0047
Serum creatinine level 2.624 (1.757–3.918) <0.0001
Estimated glomerular ﬁltration
rate
0.977 (0.966–0.988) <0.0001
B-type natriuretic peptide 1.001 (1.001–1.002) <0.0001
Norepinephrine 1.000 (1.000–1.001) 0.23
Left  ventricular end-diastolic
dimension
1.019 (0.991–1.048) 0.19
Left  ventricular ejection
fraction
0.976 (0.957–0.996) 0.022
Left  ventricular mass index 1.011 (1.004–1.018) 0.0033
Relative wall thickness 2.865 (0.443–18.514) 0.27
Left  atrial dimension 1.031 (1.005–1.057) 0.019
For continuous predictors, HR per unit is shown. HR, hazard ratio; CI, conﬁdence
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interval; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
locker; NYHA, New York Heart Association; SAS, speciﬁc activity scale.
nteraction between the risk factors and the effects of
tandard-dose carvedilol
Figs. 2 and 3 show the interaction between the factors associated
ith both clinical outcomes in a univariate analysis and the effects
f standard-dose carvedilol. If the factors are continuous variables,
he subjects were divided by the median value.
Fig. 2 shows the interaction regarding the primary outcome,
nd there was no interaction with any clinical factors except LA
imension. The administration of standard-dose carvedilol was
ssociated with unadjusted HR 0.263 (95% CI: 0.080 to 0.859)
Fig. 2A) and covariate adjusted 0.264 (0.080 to 0.876) (Fig. 2B) for
he primary outcome in the patients with LA diameter ≥ the median
alue (43.2 mm).  In contrast, unadjusted and adjusted HRs were
.123 (0.501 to 2.514) and 1.067 (0.472 to 2.412) in those with LA
able 3
esults of multivariable Cox proportional hazards models for the clinical outcomes.
HR (95% CI) p-Value
Primary endpoint
Age 1.110 (0.828–1.487) 0.49
Body mass index 0.865 (0.791–0.945) 0.0013
Diabetes mellitus 3.021 (1.730–5.263) <0.0001
Standard-dose carvedilol 0.874 (0.448–1.704) 0.69
Hemoglobin 0.913 (0.788–1.057) 0.22
Estimated glomerular ﬁltration rate 0.992 (0.979–1.006) 0.27
B-type natriuretic peptide 1.000 (1.000–1.001) 0.29
Left  ventricular mass index 1.013 (1.004–1.023) 0.0052
Left  atrial dimension 1.052 (1.021–1.085) 0.0010
Composite of cardiovascular death and unplanned hospitalization for
any cardiovascular causes
Age 1.110 (0.879–1.401) 0.38
Body mass index 0.926 (0.865–0.992) 0.028
Diabetes mellitus 2.237 (1.420–3.521) 0.0005
Standard-dose carvedilol 0.542 (0.301–0.975) 0.041
Hemoglobin 1.028 (0911–1.160) 0.65
Estimated glomerular ﬁltration rate 0.989 (0.977–1.001) 0.062
B-type natriuretic peptide 1.001 (1.000–1.002) 0.0024
Left  ventricular mass index 1.007 (0.999–1.016) 0.092
Left  atrial dimension 1.028 (1.000–1.057) 0.049
or continuous predictors, HR per unit is shown. HR, hazard ratio; CI, conﬁdence
nterval.diology 63 (2014) 424–431 427
diameter < 43.2 mm.  A p-value for interaction was 0.046 (unad-
justed) and 0.058 (adjusted).
For another major composite outcome (Fig. 3), the effects of
standard-dose carvedilol also tended to be different between the
patients with LA diameter ≥ and <43.2 mm [p = 0.076 (unadjusted,
Fig. 3A) and p = 0.12 (adjusted, Fig. 3B)]. Unadjusted and adjusted
HRs were 0.257 (0.092 to 0.715) and 0.277 (0.099 to 0.777) in those
with LA diameter ≥ 43.2 mm,  and 0.783 (0.393 to 1.561) and 0.747
(0.372 to 1.500) in those with LA diameter < 43.2 mm.
The neutral effects of standard-dose carvedilol were observed
across the other factors.
Discussion
Predictors of clinical outcomes in patients with HFPEF
Aging, decreased BMI, diabetes mellitus, anemia, renal dys-
function, elevated plasma BNP, LV hypertrophy, and LA dilatation
were risk factors for both the primary outcome and another
major composite outcome in a univariate analysis. A multivari-
able analysis revealed that decreased BMI, diabetes mellitus, and
LA dilatation were independent risk factors for both clinical out-
comes. All of the factors raised in the univariate analysis have
been reported as the risk factors for morbidity and mortality of
patients with HFPEF in studies in Western countries [5–9], and our
results conﬁrmed that the same factors are the risks for Japanese
patients with HFPEF, which is partly compatible with a previous
study in Japan [10]. Present results also indicate that the patients’
characteristics in this study are not far from those of other stud-
ies.
Obesity is a risk for incident of heart failure; however, the prog-
nosis of heart failure is better in patients with high BMI than low
BMI, and this is termed as obesity paradox [11]. An increase in
BMI  was  associated with the incidence of HFPEF in hypertensive
or diabetic Japanese patients [12,13], and the current result has
conﬁrmed that obesity paradox is also observed in Japanese HFPEF
patients. However, this does not simply indicate that a gain of
body weight improves the prognosis of HFPEF. Neither BMI  nor
triceps skinfold thickness independently predicts long-term sur-
vival of elderly patients with heart failure, whereas a larger midarm
muscle area does [14]. A recent study demonstrated that geriatric
nutritional risk index is more closely associated with mortality
of Japanese HFPEF patients than BMI  [15]. Thus, nutritional sta-
tus rather than body weight is likely to have a clinical impact on
prognosis.
The improvement in prognosis of the patients with HFREF by
-blockers is well acknowledged, and the beneﬁcial effects of -
blockers are associated with the reduction in heart rate [16]. The
Systolic Heart failure treatment with the If inhibitor ivabradine Trial
(SHIFT) reported that the heart rate reduction by a speciﬁc inhibitor
of the If current in the sinoatrial node improved the prognosis of
HFREF patients [17]. In contrast, the ivabradine-induced reduction
of heart rate did not improve the clinical outcome of patients with
coronary artery disease and reduced EF [18], and a subgroup analy-
sis of Cardiac Insufﬁciency Bisoprolol Study II (CIBIS II) showed that
the beneﬁcial effects of -blocker in HFREF cannot be attributed
only to the reduction in heart rate [19]. Therefore, the cause-
and-effect relationship between changes in heart rate and clinical
outcomes of HFREF remains unclear. In J-DHF study, the changes
in heart rate at one year after the randomization were not asso-
ciated with the clinical outcomes of HFPEF patients (Table 2), and
were not signiﬁcantly different between the control and standard-
dose groups (data not shown). Therefore, the beneﬁcial effects of
standard-dose carvedilol in HFPEF are unlikely provided through
the reduction of heart rate.
428 K. Yamamoto et al. / Journal of Cardiology 63 (2014) 424–431
Fig. 2. (A) Unadjusted analysis of the primary outcome in subgroups. (B) Adjusted analysis for prespeciﬁed covariates (age, sex, etiology, and left ventricular ejection fraction).
The  plot shows hazard ratios and 95% conﬁdence intervals. Statistical signiﬁcance for interaction implies that the factor is predictive of effective beta-blockers. Data are missing
for  some patients in some subgroups. CI, conﬁdence interval; HR, hazard ratio; BNP, B-type natriuretic peptide; LV, left ventricular.
K. Yamamoto et al. / Journal of Cardiology 63 (2014) 424–431 429
Fig. 3. (A) Unadjusted analysis of another major composite outcome in subgroups. (B) Adjusted analysis for prespeciﬁed covariates (age, sex, etiology, and left ventricular
ejection fraction). The plot shows hazard ratios and 95% conﬁdence intervals. Statistical signiﬁcance for interaction implies that the factor is predictive of effective beta-
blockers. Data are missing for some patients in some subgroups. CI, conﬁdence interval; HR, hazard ratio; BNP, B-type natriuretic peptide; LV, left ventricular.
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nteraction between the risk factors and the effects of
tandard-dose carvedilol
The elevation of plasma BNP level, LV hypertrophy, and LA
ilatation were associated with clinical outcomes in this study.
n particular, LA dilatation was an independent risk factor for
oth clinical outcomes. LA dilatation is attributed to advanced
V diastolic dysfunction and elevated LA pressure [20,21], and
V hypertrophy and elevated BNP level also indicate LV dias-
olic dysfunction in subjects with preserved EF [22,23]. It is
lausible that advanced LV diastolic dysfunction is related to
rognosis of HFPEF. The current result suggested that LA dilata-
ion interacted with the effects of standard-dose carvedilol. The
isk reduction in patients with large LA was great as com-
ared to those with small LA. Although there was no interaction
ith LV mass index or BNP level, this result suggests that the
eneﬁcial effects of standard-dose carvedilol are provided in
FPEF patients with advanced rather than mild diastolic dysfunc-
ion.
Elderly HFREF patients are at high risk of morbidity and mor-
ality; however, they are often excluded from the subjects in
andomized studies to assess the effects of pharmacological inter-
ention on HFREF, and thus, the therapeutic effects on elderly
atients are not extensively studied. This may  result in less pre-
cription of -blockers in elderly patients with heart failure [24].
n this study, the exclusion criteria did not include age, and con-
equently the median value was 73 years; the most advanced age
as 93 years in the control group and 89 years in the standard-dose
roup. The current study demonstrated that aging was  also one of
he risk factors for clinical outcomes of HFPEF patients (Table 2),
nd the lack of the interaction with age (Figs. 2 and 3) suggests that
he beneﬁcial effects of standard-dose carvedilol are expected even
n elderly patients with HFPEF.
Diabetes mellitus was one of the independent risk factors in this
tudy. Previous studies have reported that -blockers increased
he risk of subsequent onset of diabetes mellitus [25,26], and
-blockers are often avoided in patients with diabetes mellitus.
owever, a randomized trial showed that carvedilol improved glu-
ose and lipid metabolism [27]. This study showed a lack of the
nteraction of diabetes mellitus with the effects of standard-dose
arvedilol in HFPEF patients, although patients with uncontrolled
iabetes mellitus were excluded from the study. Thus, even in
FPEF patients with diabetes mellitus, standard-dose carvedilol is
xpected to provide beneﬁcial effects if diabetes mellitus is appro-
riately controlled.
Renal dysfunction and anemia were also raised as risk factors in
his study, and anemia may  be partly attributed to renal dysfunc-
ion. Previous studies have shown beneﬁcial effects of -blockers in
FREF patients with chronic kidney disease [28]. Although patients
ith severe renal dysfunction were excluded in this study, there
as no interaction between eGFR and the effects of standard-dose
arvedilol. -Blockers may  be efﬁcacious in HFPEF as well as HFREF
ven if patients have chronic kidney disease.
tudy limitations
This secondary analysis study has several limitations. First, the
-DHF study is not a community-based study. Cohort studies and
andomized clinical trials have shown different pathophysiology
f HFPEF. For example, mode of death is different among stud-
es [29,30]. The risk factors of HFPEF raised in this study may  not
e generalizable to the entire Japanese or world-wide population.
econd, the number of the study subjects was small. Third, the
ontrol group of this secondary analysis study consists of HFPEF
atients without carvedilol and with the administration of low-
ose carvedilol. Although the combined grouping was  not designeddiology 63 (2014) 424–431
before the subgroup analysis, the demographic proﬁle and the
occurrence of clinical events were compatible between HFPEF
patients without carvedilol and with the administration of low-
dose carvedilol. In addition, baseline patient characteristics of the
control and standard-dose groups in this study were not different
as shown in Table 1, and thus, such combined grouping may  not
affect the conclusion of this study.
Conclusion
Aging, decreased BMI, diabetes mellitus, anemia, renal dysfunc-
tion, increased plasma BNP, LV hypertrophy, and LA dilatation are
associated with clinical outcomes of HFPEF, and decreased BMI,
diabetes mellitus, and LA dilatation were independent risk fac-
tors. The risk reduction by standard-dose carvedilol was great in
patients with large LA as compared to those with small LA. The
current results suggest that advanced LV diastolic dysfunction as
indicated by LA dilatation exacerbates prognosis of HFPEF, and that
the standard-dose carvedilol exerts greater reduction of the inci-
dence of clinical outcomes in HFPEF patients with advanced rather
than mild diastolic dysfunction.
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